Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $6.8 million.

  • Legend Biotech's Change in Accured Expenses rose 55275.36% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year decrease of 11671.8%. This contributed to the annual value of $45.7 million for FY2024, which is 358793.89% up from last year.
  • Legend Biotech's Change in Accured Expenses amounted to $6.8 million in Q3 2025, which was up 55275.36% from $20.9 million recorded in Q2 2025.
  • Legend Biotech's Change in Accured Expenses' 5-year high stood at $77.0 million during Q4 2021, with a 5-year trough of -$39.2 million in Q1 2023.
  • In the last 5 years, Legend Biotech's Change in Accured Expenses had a median value of $7.4 million in 2024 and averaged $15.4 million.
  • As far as peak fluctuations go, Legend Biotech's Change in Accured Expenses surged by 147624.78% in 2023, and later crashed by 62350.95% in 2025.
  • Quarter analysis of 5 years shows Legend Biotech's Change in Accured Expenses stood at $77.0 million in 2021, then plummeted by 97.73% to $1.7 million in 2022, then soared by 1476.25% to $27.5 million in 2023, then plummeted by 105.36% to -$1.5 million in 2024, then skyrocketed by 558.97% to $6.8 million in 2025.
  • Its Change in Accured Expenses was $6.8 million in Q3 2025, compared to $20.9 million in Q2 2025 and -$38.6 million in Q1 2025.